August 29, 2026
RESEARCH USE ONLY. Retatrutide is an investigational compound and is not approved by the FDA for human or veterinary use. Products discussed on this site are supplied strictly for laboratory and research purposes. Nothing on this page is medical advice or a dosing recommendation for any person or animal.
Of the three comparisons people ask for in this category, this is the one with the widest gap between how confidently it is written about and how little direct evidence exists behind it.
Sourced fact: As of 19 August 2026, no trial of retatrutide versus semaglutide exists — not published, and not registered. We searched Europe PMC, the trial registries, sponsor press releases, and FDA and EMA documents. Retatrutide’s only published active-controlled trial used dulaglutide 1.5 mg as the comparator, not semaglutide. [1] The one head-to-head trial that does exist in the retatrutide program, TRIUMPH-5, compares it against tirzepatide, and has not reported. [2]
Inference: Every “retatrutide vs semaglutide” number in circulation is derived by comparing separate trials with different populations, durations, endpoints, and blinding. That method cannot establish which molecule is superior. We are not going to present one as if it can.
Three things can be compared without an indirect-comparison fallacy: what each molecule binds, what regulatory status each holds, and what tier of evidence supports each.
| Retatrutide | Semaglutide | |
|---|---|---|
| Receptors | GIPR, GLP-1R, GCGR [3] | GLP-1R only (selective) [4] |
| FDA status | Not approved for any indication [5] | Approved — Ozempic, Wegovy, Rybelsus [6] |
| Largest published trial | 537 (Phase 3, T2D) [7] | 17,604 (Phase 3, CV outcomes) [8] |
| Published obesity evidence | Phase 2, n=338 [9] | Phase 3, n=1,961 [10] |
| Cardiovascular outcomes data | Trial running, primary completion est. Feb 2029 [11] | Published; label indication granted [8] |
Inference: The evidence bases are not on the same footing. Semaglutide’s obesity data come from a 1,961-participant Phase 3 with confidence intervals; retatrutide’s peer-reviewed obesity data come from a 338-participant Phase 2 whose abstract reports no confidence intervals. Semaglutide has completed a 17,604-patient cardiovascular outcomes trial; retatrutide’s equivalent has an estimated primary completion of February 2029.
Sourced fact: Retatrutide is described by its discovery team as “a novel triple agonist peptide at the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R),” showing “balanced GCGR and GLP-1R activity but more GIPR activity.” [3]
Sourced fact: Quantified against the native hormones, retatrutide “is more potent at GIPR by a factor of 8.9, and less potent at GCGR and GLP-1R by factors of 0.3 and 0.4, respectively.” [12]
Sourced fact: Semaglutide is a selective GLP-1 receptor agonist — a single-receptor molecule.
Inference: These are pharmacologically different classes of molecule, not two versions of the same idea. Retatrutide adds GIP and glucagon receptor engagement, and its dominant activity is at GIPR — a receptor where the field has not resolved whether agonism or antagonism is the beneficial direction. Two 2025 reviews say so explicitly: “the fundamental question of whether to agonize or antagonize GIPR to treat obesity remains unanswered” [13], and “A unifying consensus… has not yet been reached.” [14]
Below are the primary endpoints as each publication states them. We have deliberately not put them in a shared table, because doing so invites exactly the comparison the data cannot support.
“At 48 weeks, the least-squares mean percentage change in the retatrutide groups was −8.7% in the 1-mg group, −17.1% in the combined 4-mg group, −22.8% in the combined 8-mg group, and −24.2% in the 12-mg group, as compared with −2.1% in the placebo group.” [9]
“The mean change in body weight from baseline to week 68 was −14.9% in the semaglutide group as compared with −2.4% with placebo, for an estimated treatment difference of −12.4 percentage points (95% CI, −13.4 to −11.5; P<0.001).” [10]
Why these are not comparable: different phase, different sample size by a factor of nearly six, different duration (48 vs 68 weeks), different populations and baseline characteristics, and only one reports a confidence interval. A difference in point estimates across trials like these is not a measured difference between the molecules.
Sourced fact: SELECT randomised 17,604 patients with cardiovascular disease and BMI ≥27 without diabetes. “A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001).” [8]
Sourced fact: The Wegovy label now includes indications spanning cardiovascular risk reduction, weight reduction in adults and patients 12 and older, and noncirrhotic MASH with F2–F3 fibrosis under accelerated approval. [6]
Sourced fact: Retatrutide’s cardiovascular and kidney outcomes trial, TRIUMPH-Outcomes (NCT06383390), enrolling approximately 10,000 participants, has an estimated primary completion date of 1 February 2029. [11]
Inference: On hard outcomes — the endpoints that matter most and take longest to measure — semaglutide has reported and retatrutide has not. That gap is roughly three years wide and no amount of cross-trial arithmetic closes it.
This is not medical advice, not a treatment comparison, and not a recommendation of either compound for any person. Semaglutide is an FDA-approved prescription medicine; questions about it belong with a licensed physician. Retatrutide is not approved for anything — see our page on retatrutide’s regulatory status.
We will write a real comparison when a real comparison exists. Until then, the accurate answer to “which is better” is that nobody has measured it.
PureLab Performance supplies retatrutide for laboratory research use. Every compound page publishes its own specification block — lot, chromatographic purity, label claim, identity method and testing laboratory — or states plainly that the certificate is pending. Related: how retatrutide works · what is semaglutide · tirzepatide vs semaglutide, where head-to-head data does exist.
RESEARCH USE ONLY — FULL DISCLAIMER. The products discussed on this page are supplied strictly for laboratory and scientific research purposes. They are not for human or veterinary use, and not for consumption. These statements have not been evaluated by the Food and Drug Administration. Nothing on this page is intended to diagnose, treat, cure, or prevent any disease in humans or animals. Nothing here constitutes medical or veterinary advice or a dosing, preparation, or administration recommendation for any person or animal.
Trial registry, label and literature searches conducted 19–20 August 2026.
